Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules

Autor: Sara S. Rinne, Wen Yin, Anna Mestre Borras, Ayman Abouzayed, Charles Dahlsson Leitao, Anzhelika Vorobyeva, John Löfblom, Stefan Ståhl, Anna Orlova, Torbjörn Gräslund

Publikováno v: Biomedicines, Vol 10, Iss 6, p 1293 (2022)

Increasing evidence suggests that therapy targeting the human epidermal growth factor receptor 3 (HER3) could be a viable route for targeted cancer therapy. Here, we studied a novel drug conjugate, ZHER3-ABD-mcDM1, consisting of a HER3-targeting affi

Externí odkaz: https://doaj.org/article/1b4f2bf682d34017b8552f583cac72d9

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer

Autor: Naoki Takegawa, Hidetoshi Hayashi, Hisato Kawakami, Junji Tsurutani, Junko Tanizaki, Kazuhiko Nakagawa, Kimio Yonesaka, Satomi Watanabe, Masayuki Takeda, Koji Haratani, Yoshikane Nonagase

Publikováno v: Cancer Medicine

HER2‐targeted therapy, especially the anti‐HER2 antibody trastuzumab, is standard for HER2‐positive breast cancer; however, its efficacy is limited in a subpopulation of patients. HER3 ligand (heregulin)‐dependent HER2‐HER3 interactions pla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dc93d4c1bf43f608fff2abc459e588e
https://doi.org/10.1002/cam4.1995

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

Autor: Andrés Cervantes, Maria Martinez-Garcia, Florence Joly, Georgina Meneses-Lorente, Maurizio Ceppi, Joan Albanell, Christelle Levy, Christoph Schindler, Iria Gonzalez, Véronique Diéras, Francesca Michielin, Annie Moisan, Celine Adessi, Martin Weisser, Wolfgang Jacob, Andreas Schneeweiss, Jose A. Lopez-Martin, Tomas Racek, Ulrik Lassen, Javier Cortes, Ian James, Max Hasmann, Tjoung-Won Park-Simon, Anja Welt, Marcus May, Frederik Marmé, Juan Miguel Cejalvo

Publikováno v: INVESTIGATIONAL NEW DRUGS
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Schneeweiss, A, Park-Simon, T W, Albanell, J, Lassen, U, Cortés, J, Dieras, V, May, M, Schindler, C, Marmé, F, Cejalvo, J M, Martinez-Garcia, M, Gonzalez, I, Lopez-Martin, J, Welt, A, Levy, C, Joly, F, Michielin, F, Jacob, W, Adessi, C, Moisan, A, Meneses-Lorente, G, Racek, T, James, I, Ceppi, M, Hasmann, M, Weisser, M & Cervantes, A 2018, ' Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer ', Investigational New Drugs, vol. 36, no. 5, pp. 848-859 . https://doi.org/10.1007/s10637-018-0562-4
Investigational New Drugs
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

Summary Purpose To investigate the safety and clinical activity of comprehensive human epidermal growth factor receptor (HER) family receptor inhibition using lumretuzumab (anti-HER3) and pertuzumab (anti-HER2) in combination with paclitaxel in patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0126ade335d0c5340693a09cb65b79e
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2445

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.